Tetrabutylammonium: a selective blocker of the somatostatin-activated hyperpolarizing current in mouse AtT-20

P Thomas1, P A Smith

  • 1Department of Pharmacology, University of Cambridge, United Kingdom. pjt28@cam.ac.uk

Insights

Somatostatin inhibits neuroendocrine cell activity by activating an inward rectifier potassium current. Tetrabutyl-ammonium (TBA+) specifically blocks this effect, revealing its role in somatostatin

Area of Science:

  • Neuroendocrinology
  • Cellular Physiology
  • Pharmacology

Background:

  • Neuroendocrine cells regulate essential bodily functions through stimulus-secretion coupling.
  • Somatostatin is a key hormone modulating these processes, but its precise mechanisms remain incompletely understood.
  • Understanding somatostatin's action on ion channels is crucial for deciphering its physiological roles.

Purpose of the Study:

  • To investigate the pharmacological properties of the somatostatin-activated inward rectifier potassium current.
  • To elucidate the role of this specific ion channel in somatostatin's modulation of stimulus-secretion coupling in AtT-20 corticotrophs.

Main Methods:

  • Utilized voltage-clamp recordings in mouse pituitary tumour cells (AtT-20 corticotrophs).
  • Examined the effects of somatostatin on membrane potential and cytosolic calcium ([Ca2+]) dynamics.
  • Tested the inhibitory effects of potassium channel blockers: tetrabutyl-ammonium (TBA+), cesium (Cs+), and tetraethyl-ammonium (TEA+).

Main Results:

  • Somatostatin induced membrane hyperpolarization and suppressed calcium spiking by activating an inward rectifier potassium current.
  • Tetrabutyl-ammonium (TBA+) selectively blocked the somatostatin-activated current and its inhibitory effects on calcium spiking.
  • Cesium (Cs+) partially blocked the inward current, while tetraethyl-ammonium (TEA+) was ineffective on the somatostatin-activated current but blocked voltage-gated outward currents.

Conclusions:

  • The somatostatin-activated inward rectifier potassium current plays a critical role in inhibiting neuroendocrine cell secretory activity.
  • Tetrabutyl-ammonium (TBA+) is a valuable pharmacological tool for dissecting the mechanisms of somatostatin action.
  • These findings provide insights into how somatostatin regulates stimulus-secretion coupling in neuroendocrine cells.

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...